These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15033810)

  • 1. Peripheral markers of apoptosis in Parkinson's disease: the effect of dopaminergic drugs.
    Blandini F; Mangiagalli A; Cosentino M; Marino F; Samuele A; Rasini E; Fancellu R; Martignoni E; Riboldazzi G; Calandrella D; Frigo GM; Nappi G
    Ann N Y Acad Sci; 2003 Dec; 1010():675-8. PubMed ID: 15033810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effect of dopaminergic treatment.
    Blandini F; Cosentino M; Mangiagalli A; Marino F; Samuele A; Rasini E; Fancellu R; Tassorelli C; Pacchetti C; Martignoni E; Riboldazzi G; Calandrella D; Lecchini S; Frigo G; Nappi G
    J Neural Transm (Vienna); 2004 Aug; 111(8):1017-30. PubMed ID: 15254790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of dopaminergic stimulation on peripheral markers of apoptosis: relevance to Parkinson's disease.
    Blandini F; Mangiagalli A; Martignoni E; Samuele A; Fancellu R; Tassorelli C; Cosentino M; Marino F; Rasini E; Calandrella D; Riboldazzi G; Colombo C; Frigo GM; Nappi G
    Neurol Sci; 2003 Oct; 24(3):157-8. PubMed ID: 14598064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopaminergic agonists in the treatment of Parkinson's disease: a review.
    Piccoli F; Riuggeri RM
    J Neural Transm Suppl; 1995; 45():187-95. PubMed ID: 8748625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral markers of oxidative stress in Parkinson's disease. The role of L-DOPA.
    Martignoni E; Blandini F; Godi L; Desideri S; Pacchetti C; Mancini F; Nappi G
    Free Radic Biol Med; 1999 Aug; 27(3-4):428-37. PubMed ID: 10468218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Controversial issues concerning the initial treatment of Parkinson's disease: L-Dopa or dopaminergic agonists?].
    Defer GL
    Rev Neurol (Paris); 1999 Jan; 155(1):43-5. PubMed ID: 10093847
    [No Abstract]   [Full Text] [Related]  

  • 7. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
    Mercuri NB; Bernardi G
    Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hallmarks of Treatment Aspects: Parkinson's Disease Throughout Centuries Including l-Dopa.
    Kim HJ; Jeon BS; Jenner P
    Int Rev Neurobiol; 2017; 132():295-343. PubMed ID: 28554412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of motor symptoms in advanced Parkinson's disease: a practical approach.
    Maranis S; Tsouli S; Konitsiotis S
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Dec; 35(8):1795-807. PubMed ID: 21645577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of dopamine receptor agonists in the treatment of early Parkinson's disease.
    Bonuccelli U; Del Dotto P; Rascol O
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S44-53. PubMed ID: 20123557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine receptor agonists in the treatment of advanced Parkinson's disease.
    Stocchi F
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S54-7. PubMed ID: 20123558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current preclinical findings on substances against Parkinson's disease].
    Gerlach M; Riederer P
    Nervenarzt; 2003 Mar; 74 Suppl 1():S2-6. PubMed ID: 12624677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Head-to-Head Comparison of the Neuropsychiatric Effect of Dopamine Agonists in Parkinson's Disease: A Prospective, Cross-Sectional Study in Non-demented Patients.
    Pérez-Pérez J; Pagonabarraga J; Martínez-Horta S; Fernández-Bobadilla R; Sierra S; Pascual-Sedano B; Gironell A; Kulisevsky J
    Drugs Aging; 2015 May; 32(5):401-7. PubMed ID: 25941103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pergolide mesylate, a dopaminergic receptor agonist, applied with L-DOPA enhances serum antioxidant enzyme activity in Parkinson disease.
    Chalimoniuk M; Stepień A; Strosznajder JB
    Clin Neuropharmacol; 2004; 27(5):223-9. PubMed ID: 15602103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of dopamine agonists in early Parkinson's disease.
    Watts RL
    Neurology; 1997 Jul; 49(1 Suppl 1):S34-48. PubMed ID: 9222273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease.
    Torstenson R; Hartvig P; Långström B; Westerberg G; Tedroff J
    Ann Neurol; 1997 Mar; 41(3):334-40. PubMed ID: 9066354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy.
    Fischer PA
    J Neural Transm Suppl; 1995; 46():381-9. PubMed ID: 8821073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between temperament and depression in Parkinson's disease patients under dopaminergic treatment.
    Dogan B; Akyol A; Memis CO; Sair A; Akyildiz U; Sevincok L
    Psychogeriatrics; 2019 Jan; 19(1):73-79. PubMed ID: 30141277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Medicinal treatment of idiopathic Parkinson's disease].
    Klockgether T
    Nervenarzt; 2003 Mar; 74 Suppl 1():S12-21. PubMed ID: 12624679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.